These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8621850)

  • 1. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.
    Kane GC; Pollice M; Kim CJ; Cohn J; Dworski RT; Murray JJ; Sheller JR; Fish JE; Peters SP
    J Allergy Clin Immunol; 1996 Feb; 97(2):646-54. PubMed ID: 8621850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
    Kane GC; Tollino M; Pollice M; Kim CJ; Cohn J; Murray JJ; Dworski R; Sheller J; Fish JE; Peters SP
    Prostaglandins; 1995 Jul; 50(1):1-18. PubMed ID: 8588068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics.
    Hasday JD; Meltzer SS; Moore WC; Wisniewski P; Hebel JR; Lanni C; Dubé LM; Bleecker ER
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1229-36. PubMed ID: 10764316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
    Liu MC; Dubé LM; Lancaster J
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.
    Abraham WM; Ahmed A; Cortes A; Sielczak MW; Hinz W; Bouska J; Lanni C; Bell RL
    Eur J Pharmacol; 1992 Jul; 217(2-3):119-26. PubMed ID: 1330588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
    Grissom CK; Richer LD; Elstad MR
    Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
    Wenzel SE; Trudeau JB; Kaminsky DA; Cohn J; Martin RJ; Westcott JY
    Am J Respir Crit Care Med; 1995 Sep; 152(3):897-905. PubMed ID: 7663802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study.
    Chen DL; Huang HJ; Byers DE; Shifren A; Belikoff B; Engle JT; Arentson E; Kemp D; Phillips S; Scherrer DE; Fujiwara H; Spayd KJ; Brooks FJ; Pierce RA; Castro M; Isakow W
    PLoS One; 2018; 13(2):e0191783. PubMed ID: 29414995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E; Cohn J; Dubé L; Drazen JM
    JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.
    Calhoun WJ; Lavins BJ; Minkwitz MC; Evans R; Gleich GJ; Cohn J
    Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1381-9. PubMed ID: 9603112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
    Israel E; Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Shapiro J; Cohn J; Rubin P; Drazen JM
    Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
    Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
    Woodruff PG; Albert RK; Bailey WC; Casaburi R; Connett JE; Cooper JA; Criner GJ; Curtis JL; Dransfield MT; Han MK; Harnden SM; Kim V; Marchetti N; Martinez FJ; McEvoy CE; Niewoehner DE; Reilly JJ; Rice K; Scanlon PD; Scharf SM; Sciurba FC; Washko GR; Lazarus SC;
    COPD; 2011 Feb; 8(1):21-9. PubMed ID: 21299475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
    Meltzer SS; Hasday JD; Cohn J; Bleecker ER
    Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
    Hui KP; Taylor IK; Taylor GW; Rubin P; Kesterson J; Barnes NC; Barnes PJ
    Thorax; 1991 Mar; 46(3):184-9. PubMed ID: 1851340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge.
    Ohnishi T; Sur S; Collins DS; Fish JE; Gleich GJ; Peters SP
    J Allergy Clin Immunol; 1993 Oct; 92(4):607-15. PubMed ID: 8409120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation.
    Peebles RS; Liu MC; Adkinson NF; Lichtenstein LM; Hamilton RG
    J Allergy Clin Immunol; 1998 Feb; 101(2 Pt 1):265-73. PubMed ID: 9500761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
    Hackshaw KV; Shi Y; Brandwein SR; Jones K; Westcott JY
    J Rheumatol; 1995 Mar; 22(3):462-8. PubMed ID: 7783062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological modulation of eosinophil influx into the lungs of Brown Norway rats.
    Namovic MT; Walsh RE; Goodfellow C; Harris RR; Carter GW; Bell RL
    Eur J Pharmacol; 1996 Nov; 315(1):81-8. PubMed ID: 8960868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects.
    Larsson BM; Kumlin M; Sundblad BM; Larsson K; Dahlén SE; Palmberg L
    Respir Med; 2006 Feb; 100(2):226-37. PubMed ID: 15939582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.